Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

Inclusion Criteria: * Men and women aged 20 years or older diagnosed with type 2 diabetes. * subjects having a level of glycated hemoglobin (HbA1c) 7.0% or more, and 10% or less. * subjects having urine albumin to creatinine ratio (UACR) 30 ug/mg or more, and 3000 ug/mg or less. * subjects having estimated glomerular filtration rate (eGFR) 30 or more. * subjects who had taken angiotensin II receptor blocker(ARB) or angiotensin-converting enzyme(ACE) inhibitors for more than 4 weeks. * subjects having body mass index (BMI) 20kg/m2 or more, 40 kg/m2 or less. * subjects who entirely understood all the process of clinical study protocol and voluntarily take part in the study and agree to follow rule of the study. Exclusion Criteria: * subjects having type 1 diabetes, secondary diabetes, or gestational diabetes * subjects who had a history of surgery of resection of more than a half length of stomach or intestine. * subjects having more than three-fold higher levels of Aspartate Transaminase(AST) or Alanine Transaminase(ALT) than upper normal limit. * subjects who had taken Dipeptidyl Peptidase4(DPP4)-inhibitor or glucagon-like peptide-1(GLP-1) analogue within 8 weeks prior to screening. * subjects who had taken oral triple hypoglycemic agents within 8 weeks prior to screening * subjects taking strong cytochrome P450 3A4(CYP3A4) inhibitors or strong cytochrome P450 3A4(CYP3A4) inducers * subjects who are pregnants or breast feeding givers. * subjects who are unsuitable for clinical trial participation based on clinical laboratory test results or other reasons (e.g. taking chemotherapy or radiation for treatment for cancers).